reason report
solid finish outlook look conserv pt
bottom line reiter op increas pt
vs view new product cycl share
gain opportun across busi continu
sustain best-in-class hsd revenue growth profil along dd
ep out-performance mark revenue ep growth
lend support thesi view enough satisfi
believ high expect print also think
compani outlook in-lin org revenue ahead ep
view investor conserv beatabl start point
year stand-alon ep forecast
increas believ qtr management confer call commentari
highlight underli health/strength stand-alon basi
ex-wmgi could allevi investor anxieti around anticip
margin/ep dilut pend mp transact pt
increas roll-forward valuat slightli higher
beat oper out-performance slightli lower
tax y/i org revenue mark consecut qtr hsd growth
revenu beat consensu dollar basi
org cc growth org cc vs rel consensu
neuro/spin org cc ortho org cc beat
medsurg org cc under-perform gm
consensu oper margin basic line
y/i ultim sale out-performance coupl
lower interest/oth expens tax rate vs consensu
help adj ep beat
stand-alone outlook bracket street org cc growth
view management issu stand-alone organ cc revenue growth
cc vs our/consensu includ extra sell day
assum nomin fx impact full year
note management start cc org guid
deliv think see similar beat
rais progress furthermor ceo lobo emphas
feel good better busi momentum driver
macro backdrop head head
guidanc rang issu stand-alone oper
margin expect see improv
expect deliv posit op leverag
rang stand-alone adj ep guidanc expect
captur consensu low end rang
net debt total capit
price-to-earnings lt ep growth
medic suppli devic
ep
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million ep present cash
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
assum tax rate rang management
expect adj ep consensu combin
basi management still expect transact neutral
ep dilut ep accret thereaft
continu take share us knee mako momentum help
acceler us knee franchis dd growth territori mako
hip demand/util continu increas underscor y/
growth hip procedur mako us knee growth
y/i vs us hip growth y/i
vs management indic mako sale increas robot
util across joint applic drive continu impress
share gain respect broader ortho market management continu
see solid perform australia canada europ even though
trauma/extrem came our/consensu think management
concern perform indic busi
difficult y/i comp t/e futur outlook new product
ramp launch alpha mini fragment system
mako strength continu anoth qtr solid procedures/
util plu big sequenti uptick placement strongest qtrli
capit placement ever place ww/u robot vs
continu sell signific
robot competit account acct lower market
share mako global instal base approxim close
system us management indic mako pipelin
remain strong total knee applic tka drove meaning
increment share gain y/i mako tka
perform full year mako tka procedur y/i top
demand cementless knee continu climb
exit year us knee procedur management indic
expect continu take share knee driven mako
perform integr get back track neurotech/
spine grew org cc vs anniversari
hemorrhag ischem stroke neuro-pow instrument product
integr effort back track full year pf basi deliv
lsd growth ww basi
sale endoscopi y/i cc driven strength us
y/i partial off-set weak ou us endoscopi reflect
strength across product line highlight dd growth video product
includ camera camera launch late
ramp meaning instrument
led impress gain wast manag product steri-
shield smoke evacu medic largest
underperform despit solid perform bed
rate share outperform price target remain one
higher qualiti compani large-cap med-tech univers today increasingli
diversifi medic devic compani one believ like drive least mid high-
singl digit top-lin high-singl digit low dd digit bottom-lin growth compound-annual-growth-rate
next two year view one best posit compani large-
cap univers sustain upper-ti organ sales/ebitda/ep growth drive sharehold
return given new product cycl across divis help support division
sale growth rate key end-market grow exposure/market share within
robot on-going cost/expens optim effort expect help yield least
underli annual ebita margin expans compani get past deal
relat dilut increas growth contribut physio-control invuiti
acquisit eventu long-term potenti gener signific
increment revenu mako platform spine extrem investor increasingli
focu sale growth factor oper leverag opportun futur
believ stock move higher
current share trade forward cash ep repres
discount large-cap med-tech peer group averag alc
snn ew given averag
sale growth prospect think in-lin multipl arguabl premium warrant
confid syk average sale growth sustain profit earn growth
prospect capabl track least line large- cap med-tech peer
group averag faster given potenti revenu upsid year
potenti invest erp transatlant cost initi yield meaning
oper leverag futur given stabil compani top line new product
way/rec launch think trade least line peer group average
appli price-to-earnings multipl ep yield pt
risk valuat includ prolong pullback possibl deterior hospit
purchas trend limit upsid potenti medsurg estim unabl
success adapt mako platform new ortho indic time fashion new
entrant orthoped hip/kne robot segment elong capit sell cycl hinder
syk share gain momentum ortho recon transact result bigger dis-
synergi manag origin assumpt call and/or dilut wors expect
either due integr disrupt requir divestitur origin contempl
deal take longer close expect new product launch robot system
hd camera new trauma nail launch success forecast gener
increas sale momentum unabl deliv oper leverag and/or dd
ep growth despit sustain above-averag top-lin growth rate
million except ep
compani report factset consensu svb leerink llc research
million except ep
margin sale
compani report svb leerink llc research
million except per share
net sale report
net sale adj
sale
earn incom tax
earn incom tax
sale report
sale adj
earn incom tax
compani report svb leerink llc estim
million
total sale report
total sale adj
total sale adj
compani report svb leerink llc estim
report number adjust
account chang purpos
